Dipeptidyl peptidase-4 inhibitors are effective in Japanese type 2 diabetic patients with sustained endogenous insulin-secreting capacity, a higher body mass index and insulin resistance

Journal of Diabetes Investigation

Volumn 4, Issue 2, 2013, Pages 190-194

  Kozawa, Junji ^a   Kitamura, Tetsuhiro ^a   Nishizawa, Hitoshi ^a   Yasuda, Tetsuyuki ^a   Maeda, Norikazu ^a   Otsuki, Michio ^a   Okita, Kohei ^a   Iwahashi, Hiromi ^a   Kaneto, Hideaki ^a   Funahashi, Tohru ^a,b   Imagawa, Akihisa ^a   Shimomura, Iichiro ^a  

^a Department of Metabolic Medicine ^*  (Japan)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Dipeptidyl peptidase 4 inhibitor; Insulin secretion; Type 2 diabetes

Indexed keywords

ALOGLIPTIN; ALPHA GLUCOSIDASE INHIBITOR; BIGUANIDE; C PEPTIDE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLITAZONE DERIVATIVE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; PHENYLALANINE DERIVATIVE; SITAGLIPTIN; SULFONYLUREA; VILDAGLIPTIN;

ADULT; AGED; ARTICLE; BODY MASS; C PEPTIDE INDEX; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC DIET; DRUG EFFICACY; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HOMEOSTASIS MODEL ASSESSMENT FOR INSULIN RESISTANCE; HUMAN; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SECRETING CAPACITY; INSULINOGENIC INDEX II; JAPANESE; LENGTH OF STAY; MALE; MEDICAL RECORD REVIEW; METABOLIC PARAMETERS; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTPRANDIAL STATE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

EID: 84878354907     PISSN: 20401116     EISSN: 20401124     Source Type: Journal    
DOI: 10.1111/jdi.12016     Document Type: Article

References (20)

1. Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001; 414: 782-787.
2. Ministry of Health, Labour and Welfare of Japan. Outline for the Results of the National Health and Nutrition Survey of Japan2007. Available at http://www.nih.go.jp/eiken/english/research/pdf/nhns2007.pdf (last accessed on 2012, May 9).
3. Chan JC, Malik V, Jia W, et al. Diabetes in Asia: epidemiology, risk factors, and pathophysiology. JAMA 2009; 301: 2129-2140.
4. Aschner P, Kipnes MS, Lunceford JK, et al. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 2006; 29: 2632-2637.
5. Bosi E, Camisasaca RP, Collober C, et al. Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care 2007; 30: 890-895.
6. DeFronzo RA, Fleck PR, Wilson CA, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study. Diabetes Care 2008; 31: 2315-2317.
7. Qian L, Xu L, Wang X, et al. Early insulin secretion failure leads to diabetes in Chinese subjects with impaired glucose regulation. Diabetes Metab Res Rev 2009; 25: 144-149.
8. Fukushima M, Usami M, Ikeda M, et al. Insulin secretion and insulin sensitivity at different stages of glucose tolerance: a cross-sectional study of Japanese type 2 diabetes. Metabolism 2004; 53: 831-835.
9. Toyoda K, Fukushima M, Mitsui R, et al. Factors responsible for age-related elevation in fasting plasma glucose: a cross-sectional study in Japanese men. Metabolism 2008; 57: 299-303.
10. Maeda T, Kubota A, Tanaka Y, et al. The safety, efficacy and predictors for HbA1c reduction of sitagliptin in the treatment of Japanese type 2 diabetes. Diabetes Res Clin Pract 2012; 95: e20-e22.
11. Nomiyama T, Akehi Y, Takenoshita H, et al. Contributing factors related to efficacy of the dipeptidyl peptidase-4 inhibitor sitagliptin in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract 2012; 95: e27-e28.
12. Bando Y, Kanehara H, Aoki K, et al. Obesity may attenuate the HbA1c-lowering effect of sitagliptin in Japanese type 2 diabetic patients. J Diabetes Invest 2012; 3: 170-174.
13. Rossetti L, Giaccari A, DeFronzo RA. Glucose toxicity. Diabetes Care 1990; 13: 610-630.
14. Asano T, Kawamura M, Watanabe T, et al. Indices of urinary and serum C-peptide corrected with fasting plasma glucose for decision-making of insulin therapy in type 2 diabetes-validation and comparison. J Japan Diab Soc 2008; 51: 759-763.
15. Kozawa J, Inoue K, Iwamoto R, et al. Liraglutide is effective in type 2 diabetic patients with sustained endogenous insulin secretion capacity. J Diabetes Invest 2012; 3: 294-297 (in press).
16. Funahashi T, Matsuzawa Y. Metabolic syndrome: clinical concept and molecular basis. Ann Med 2007; 39: 482-494.
17. Shimajiri Y, Tsunoda K, Furuta M, et al. Prevalence of metabolic syndrome in Japanese type 2 diabetic patients and its significance for chronic vascular complications. Diabetes Res Clin Pract 2008; 79: 310-317.
18. Kikuchi M, Abe N, Kato M, et al. Vildagliptin dose-dependently improves glycemic control in Japanese patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 2009; 83: 233-240.
19. Kozawa J, Okita K, Imagawa A, et al. Similar incretin secretion in obese and non-obese Japanese subjects with type 2 diabetes. Biochem Biophys Res Commun 2010; 393: 410-413.
20. Cho YM, Kieffer TJ. New aspects of an old drug: metformin as a glucagon-like peptide 1 (GLP-1) enhancer and sensitiser. Diabetologia 2011; 54: 219-222.